Effectiveness of including azoximer bromide in the standard management of ICU patients with severe COVID-19


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The severe course of COVID-19 is often accompanied by the development of acute respiratory distress syndrome and leads to high rates of death. The objective of our study was to evaluate the effectiveness of including azoximer bromide in the standard management of ICU patients with severe COVID-19 complicated by the development of bilateral polysegmental viral pneumonia. Material and methods. An open, non-randomized, observational, single-centre, prospective study of the effectiveness of adding azoximer bromide (Polyoxidonium®, 6 mg 3 times a day intramuscularly for 4 days) into the complex therapy of patients hospitalized in the ICU of City Clinical Hospital No. 24 (Moscow) with a new coronavirus infection COVID-19 (virus identified) and bilateral polysegmental viral pneumonia (study group, n=12), followed by a comparative analysis of the results obtained in a randomized retrospective pharmacoepidemiological study (control group, n=20). Results. The average age of patients in the control group was 70,7 (+12,5) years, in the study group - 66,75 (±14,5) years. The survived patients in the control group were 35% versus 50% in the study. The need for mechanical ventilation in the control group during the stay in the ICU was observed in 90% versus 58,3% of patients in the study group. The incidence of sepsis was 65% for the control group and 25% for the study; septic shock was registered only in patients of the control group (25%). Conclusion. The results showed an increase in the proportion of patients who survived in the group treated with Polyoxidonium®, against the background of a significantly lower number of episodes of sepsis, the absence of septic shock and less need for mechanical ventilation.

Full Text

Restricted Access

About the authors

S. K Zyryanov

Peoples' Friendship University of Russia; City Clinical Hospital No. 24 of the Department of Healthcare of Moscow

Email: zyryanov_sk0rudn.university
127015, Moscow, 10 Pistsovaya Str.; 117198, Moscow, 8 Miklukho-Maklaya Str

O. I Butranova

Peoples' Friendship University of Russia

Email: butranova-oi@rudn.ru
127015, Moscow, 10 Pistsovaya Str

References

  1. Ярилин А.А. Иммунология. М.: ГЭОТАР-Медиа. - 2010. - с. 752. - C. 520.
  2. Инструкция по медицинскому применению препарата Полиоксидоний®
  3. Маланичева Т.Г., Агафонова Е.В. Эффективность иммуномодулирующей терапии внебольничной пневмонии у часто болеющих детей. // Детские инфекции. - 2018. -17 (4). - с. 38-43
  4. Караулов А.В., Горелов А.В. Применение азоксимера бромида втерапии инфекционновоспалительных заболеваний органов дыхания у детей: мета-анализ контролируемых клинических исследований. Журнал инфектологии. Том 11, №4, 2019.с.31-41
  5. Li J., Huang D.Q., Zou B., Yang H., Hui W.Z., Rui F., Yee N.T.S., Liu C., Nerurkar S.N., Kai J.C.Y., Teng M.L.P., Li X., Zeng H., Borghi J.A., Henry L., Cheung R., Nguyen M.H. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021 Mar;93(3):1449-1458. doi: 10.1002/jmv.26424.
  6. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi: 10.1001/jama.2020.2648
  7. Stokes E.K., Zambrano L.D., Anderson K.N. et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(24):759-765. doi: 10.15585/mmwr.mm6924e2
  8. Hendrickson K.W., Peltan I.D., Brown S.M. The Epidemiology of Acute Respiratory Distress Syndrome Before and After Coronavirus Disease 2019. Crit Care Clin. 2021;37(4):703-716. doi: 10.1016/j.ccc.2021.05.001
  9. Tzotzos S.J., Fischer B., Fischer H., Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care. 2020;24(1):516. doi: 10.1186/s13054-020-03240-7
  10. Wang Y., Lu X., Li Y. et al. Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. Am J Respir Crit Care Med. 2020;201(11):1430-1434. doi: 10.1164/rccm.202003-0736LE
  11. Gujski M., Jankowski M., Rabczenko D. Gory 'nski P., Juszczyk, G. The Prevalence of Acute Respiratory Distress Syndrome (ARDS) and Outcomes in Hospitalized Patients with COVID-19-A Study Based on Data from the Polish National Hospital Register. Viruses 2022, 14, 76. https://doi.org/10.3390/v14010076
  12. Hasan S.S., Capstick T., Ahmed R., Kow C.S., Mazhar F., Merchant H.A., Zaidi S.T.R. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med. 2020 Nov;14(11):1149-1163. doi: 10.1080/17476348.2020.1804365.
  13. Mahat R.K., Panda S., Rathore V., Swain S., Yadav L., Sah S.P. The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: A systematic review and meta-analysis. Clin Epidemiol Glob Health. 2021;11:100727. doi: 10.1016/j.cegh.2021.100727
  14. Parimoo A., Biswas A., Baitha U. et al. Dynamics of Inflammatory Markers in Predicting Mortality in COVID-19. Cureus. 2021;13(10):e19080. doi: 10.7759/cureus.19080
  15. Mohanty R.R., Das S., Padhy B.M., Meher B.R.Comparison of Clinical Outcome between Dexamethasone and Methyl Prednisolone in Treatment of Moderate to Severe COVID-19: A Systematic Review and Meta-Analysis. J Assoc Physicians India. 2022 Jan;70(1):11-12.
  16. Pinzon M.A., Ortiz S., Holguin H., Betancur J.F., Cardona Arango D., Laniado H., Arias Arias C., Munoz B., Quiceno J., Jaramillo D., Ramirez Z. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS One. 2021 May 25;16(5):e0252057. doi: 10.1371/journal.pone.0252057.
  17. Ko J.J., Wu C., Mehta N., Wald-Dickler N., Yang W., Qiao R. A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19. J Intensive Care Med. 2021 Jun;36(6):673-680. doi: 10.1177/0885066621994057.
  18. Wagner C., Griesel M., Mikolajewska A., Mueller A., Nothacker M., Kley K., Metzendorf M.I., Fischer A.L., Kopp M., Stegemann M., Skoetz N., Fichtner F. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Aug 16;8(8):CD014963. doi: 10.1002/14651858.CD014963.
  19. Lomakin N.V., Bakirov B.A., Protsenko D.N. et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflamm Res. 2021 Dec;70(10-12):1233-1246. doi: 10.1007/s00011-021-01507-5.
  20. Salama C., Han J., Yau L. et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021;384(1):20-30. doi: 10.1056/NEJMoa2030340
  21. Chamlagain R., Shah S., Sharma Paudel B., Dhital R., Kandel B. Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review.Interdiscip Perspect Infect Dis. 2021;2021:8903435. doi: 10.1155/2021/8903435
  22. Hall M.W., Joshi I., Leal L., Ooi E.E. Immune Immunomodulation in Coronavirus Disease 2019 (COVID-19): Strategic Considerations for Personalized Therapeutic Intervention. Clin Infect Dis. 2022;74(1):144-148. doi: 10.1093/cid/ciaa904
  23. Петров Р.В., Хаитов Р.М., Некрасов А.В., Атаулаханов Р.И., Пинегин Б.В., Пучкова А.С. и др. Полиоксидоний - иммуномодулятор последнего поколения: итоги трехлетнего клинического применения. Аллергия, астма и клиническая иммунология. 1999;(3):3-6 @@Petrov R.V., Khaitov R.M., Nekrasov A.V., Ataullakhanov R.I., Pinegin B.V., Puchkova A.S. et al. Polyoxidonium, a New-Generation Immunomodulator: Experience From a Three Years Clinical Application. Allergiya, astma i klinicheskaya immunologiya = Allergies, Asthma and Clinical Immunology. 1999;(3):3-6.(In Russ.)
  24. Toptygina A., Semikina E., Alioshkin V. Influence of an immunopotentiator Polyoxidonium on cytokine profile and antibody production in children vaccinated with Priorix. Arch Physiol Biochem. 2012;118(4):197-203. https://doi.org/10.3109/13813455.2012.659669
  25. Grivtsova L.Y., Falaleeva N.A., Tupitsyn N.N. Azoximer Bromide: Mystery, Serendipity, and Promise. Front Oncol. 2021;11:699546. https://doi.org/10.3389/fonc.2021.699546
  26. Efimov S.V., Matsiyeuskaya N.V., Boytsova O.V., Akhieva L.Y., Kvasova E.I., Harrison F, Karpova YS, Tikhonov A, Khomyakova NF, Hardman T, Rossi JF. The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical]. Drugs Context. 2021;10:2020-11-1. doi: 10.7573/dic.2020-11-1
  27. Efimov S.V., Matsiyeuskaya N.V., Boytsova O.V. et al. Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19. Drugs Context. 2022;11:2022-1-1. doi: 10.7573/dic.2022-1-1
  28. Мавзютова Г.А., Мухамадиева Л.Р., Фазлыева Р.М., Мирсаева Г.Х., Тюрина Е.Б. Рациональная иммунокоррекция в комплексной терапии внебольничной пневмонии. Медицинский Совет. 2015;(16):68-73. @@Mavzyutova G.A., Mukhamadieva L.R., Fazlyeva R.M., Mirsaeva G.K., Tyurina E.B. Rational immunotherapy in the combination treatment of community-acquired pneumonia. Meditsinskiy sovet = Medical Council. 2015;(16):68-73. (In Russ.)]. https://doi.org/10.21518/2079-701X-2015-16-68-73.
  29. Мавзютова Г.А., Мухамадиева Л.Р., Фазлыева Р.М. Клинический подход к иммунокоррекции при внебольничной пневмонии. Медицинский Совет. 2017;(11):58-63. @@Mavzyutova G.A., Mukhamadieva L.R., Fazlyeva R.M. Clinical approash to immunocorrection in communiti-acquired pneumonia. Meditsinskiy sovet = Medical Council. 2017;(11):58-63. (In Russ.)]. https://doi.org/10.21518/2079-701X-2017-11-58-63.
  30. Зырянов С.К., Бутранова О.И., Ершов А.В., Манасова З.Ш. Эффективность азоксимера бромида в терапии госпитализированных пациентов с внебольничной пневмонией среднетяжелого и тяжелого течения. Медицинский Совет. 2021; (18) :106-117. @@Zyryanov S.K., Butranova O.I., Ershov A.V., Manasova Z.S. Efficacy of azoximer bromide in the treatment of hospitalized patients with moderate to severe community-acquired pneumonia. Meditsinskiy sovet = Medical Council. 2021;(18):106-117. (In Russ.)]. https://doi.org/10.21518/2079-701X-2021-18-106-117.
  31. https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/211/original/BMP-13.pdf
  32. Shi C., Wang L., Ye J. et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):663. doi: 10.1186/s12879-021-06369-0
  33. Li X., Zhong X., Wang Y., Zeng X., Luo T., Liu Q. Clinical determinants of the severity of COVID-19: A systematic review and metaanalysis. PLoS One. 2021;16(5):e0250602. doi: 10.1371/journal.pone.0250602
  34. Ou M., Zhu J., Ji P. et al. Risk factors of severe cases with COVID-19: a meta-analysis. Epidemiol Infect. 2020;148:e175. doi: 10.1017/S095026882000179X
  35. Katzenschlager S., Zimmer A.J., Gottschalk C. et al. Can we predict the severe course of COVID-19 - a systematic review and metaanalysis of indicators of clinical outcome?. PLoS One. 2021;16(7):e0255154. doi: 10.1371/journal.pone.0255154
  36. Naeini M.B., Sahebi M., Nikbakht F. et al. A meta-meta-analysis: Evaluation of meta-analyses published in the effectiveness of cardiovascular comorbidities on the severity of COVID-19. Obes Med. 2021;22:100323. doi: 10.1016/j.obmed.2021.100323
  37. Zhang X., Lewis A.M., Moley J.R., Brestoff J.R. A systematic review and meta-analysis of obesity and COVID-19 outcomes. Sci Rep. 2021;11(1):7193. doi: 10.1038/s41598-021-86694-1
  38. Rahim F., Amin S., Noor M. et al. Mortality of Patients With Severe COVID-19 in the Intensive Care Unit: An Observational Study From a Major COVID-19 Receiving Hospital. Cureus. 2020;12(10):e10906. doi: 10.7759/cureus.10906
  39. Wu C., Chen X., Cai Y. et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China [published correction appears in JAMA Intern Med. 2020 Jul 1;180(7):1031
  40. Tzotzos S.J., Fischer B., Fischer H., Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care. 2020;24(1):516. doi: 10.1186/s13054-020-03240-7
  41. Leonard-Lorant I., Delabranche X., Severac F. et al. Acute Pulmonary Embolism in Patients with COVID-19 at CT Angiography and Relationship to d-Dimer Levels. Radiology. 2020;296(3):E189-E191. doi: 10.1148/radiol.2020201561
  42. Poyiadji N., Cormier P., Patel P.Y. et al. Acute Pulmonary Embolism and COVID-19. Radiology. 2020;297(3):E335-E338. doi: 10.1148/radiol.2020201955
  43. Desai R., Gandhi Z., Singh S. et al. Prevalence of Pulmonary Embolism in COVID-19: a Pooled Analysis. SN Compr Clin Med. 2020;2(12):2722-2725. doi: 10.1007/s42399-020-00605-5
  44. Grasselli G., Scaravilli V., Mangioni D. et al. Hospital-Acquired Infections in Critically Ill Patients With COVID-19. Chest. 2021;160(2):454-465. doi: 10.1016/j.chest.2021.04.002
  45. Ketcham S.W., Bolig T.C., Molling D.J., Sjoding M.W., Flanders S.A., Prescott H.C. Causes and Circumstances of Death among Patients Hospitalized with COVID-19: A Retrospective Cohort Study. Ann Am Thorac Soc. 2021 ;18(6):1076-1079. doi: 10.1513/AnnalsATS.202011-1381RL
  46. Bardi T., Pintado V., Gomez-Rojo M. et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis. 2021;40(3):495-502. doi: 10.1007/s10096-020-04142-w
  47. Hariyanto T.I., Japar K.V., Kwenandar F. et al. Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis. Am J Emerg Med. 2021;41:110-119. doi: 10.1016/j.ajem.2020.12.076
  48. Henry B.M., Aggarwal G., Wong J. et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med. 2020;38(9):1722-1726. doi: 10.1016/j.ajem.2020.05.073
  49. Martha J.W., Wibowo A., Pranata R. Prognostic value of elevated lactate dehydrogenase in patients with COVID-19: a systematic review and meta-analysis [published online ahead of print, 2021 Jan 15]. Postgrad Med J. 2021 ;postgradmedj-2020-139542. doi: 10.1136/postgradmedj-2020-139542
  50. Huang Y., Zhang Y., Ma L. Meta-analysis of laboratory results in patients with severe coronavirus disease 2019. Exp Ther Med. 2021;21(5):449. doi: 10.3892/etm.2021.9877
  51. Kazemi E., Soldoozi Nejat R., Ashkan F., Sheibani H. The laboratory findings and different COVID-19 severities: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2021 Mar 16;20(1):17. doi: 10.1186/s12941-021-00420-3.
  52. Huang G., Kovalic A.J., Graber C.J. Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease Severity. Emerg Infect Dis. 2020;26(8):1839-1841. doi: 10.3201/eid2608.201160
  53. Yamada T., Wakabayashi M., Yamaji T., Chopra N., Mikami T., Miyashita H., Miyashita S. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis. Clin Chim Acta. 2020 Oct;509:235-243. doi: 10.1016/j.cca.2020.06.008.
  54. Zhao Q., Meng M., Kumar R. et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis.Int J Infect Dis. 2020;96:131-135. doi: 10.1016/j.ijid.2020.04.086
  55. Huang I., Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care. 2020;8:36. Published 2020 May 24. doi: 10.1186/s40560-020-00453-4
  56. Toori K.U., Qureshi M.A., Chaudhry A. Lymphopenia: A useful predictor of COVID-19 disease severity and mortality. Pak J Med Sci. 2021;37(7):1984-1988. doi: 10.12669/pjms.37.7.4085
  57. Ghahramani S., Tabrizi R., Lankarani K.B., Kashani S.M.A., Rezaei S., Zeidi N., Akbari M., Heydari S.T., Akbari H., Nowrouzi-Sohrabi P., Ahmadizar F. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and metaanalysis. Eur J Med Res. 2020 Aug 3;25(1):30. doi: 10.1186/s40001-020-00432-3.
  58. Ou M., Zhu J., Ji P. et al. Risk factors of severe cases with COVID-19: a meta-analysis. Epidemiol Infect. 2020;148:e175. doi: 10.1017/S095026882000179X
  59. Kaushal K., Kaur H., Sarma P. et al. Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. J Crit Care. 2022;67:172-181. doi: 10.1016/j.jcrc.2021.09.023.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies